CME and CFTC Clash Over On-Chain Perpetual Futures

The CME Group, the largest derivatives exchange operator in the US, is locked in a battle with its regulator, the Commodity Futures Trading Commission (CFTC), over the introduction of blockchain-based perpetual futures products. The CFTC recently approved the listing of crypto perpetual futures, also known as perps, on the prediction markets platform Kalshi and cryptocurrency exchange Coinbase. However, the CME Group has sued the CFTC, arguing that the regulator is mislabeling these products and misapplying the law. The CME claims that perps are harmful to its long-dated futures products and that the CFTC's approval did not consider the potential consequences. The dispute has significant implications for the US approach to the rapidly growing market for perpetual futures, with non-US perps volume reportedly reaching $60 trillion in volume last year. The CME Group's chairman, Terry Duffy, has stated that the definition of a swap is clear and that the CFTC did not follow the proper protocol in approving the perps. He also expressed concerns about the CFTC's ability to enforce its emerging perps policy and prevent non-US traders from trading on CFTC-regulated platforms. The CFTC's chairman, Mike Selig, has defended the regulator's decision, stating that the CME's lawsuit is an attempt to undermine the agency's efforts to undertake a reasoned analysis of the critical issues at stake. The dispute has sparked frustration among supporters of the CFTC's reforming agenda, with some arguing that the CME is trying to use regulation to stifle competition. The future of CFTC-driven perps remains uncertain as the CME prepares its case, which includes claims that the agency rubber-stamped the Kalshi application. The outcome of the dispute could have significant implications for the US derivatives market and the growing demand for perpetual futures products.